Detection and evaluation of antibody formation against biologics in psoriasis

Detection and evaluation of antibody formation against biologics in psoriasis - evaluation of antibody formation against biologics in psoriasis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35618

Enrollment

240

Registered

2010-05-19

Start date

2008-06-12

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Written informed consent - Patients diagnosed with chronic plaque type psoriasis - Treatment with a biologic (etanercept, adalimumab, infliximab or efalizumab) for chronic moderate to severe plaque psoriasis started not longer than 52 weeks before. - Consecutive patients starting treatment with a biologic (etanercept, adalimumab, infliximab or efalizumab) for chronic plaque psoriasis.

Exclusion criteria

Exclusion criteria: - Previous treatment with the same biologic. - Patients unable to comply with the requirements of the study

Design outcomes

Primary

Measure	Time frame
The serum level of antibodies against the concerning biologic.	—

Secondary

Measure	Time frame
The disease severity objectivated by the PASI in patients with antibodies to biologics compared to patients without antibodies to biologics at several timepoints.	—

Countries

Netherlands

Outcome results